Type 2 Diabetes Trial, Recruiting NCT03865914 Sponsor: Chinese PLA General Hospital Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT03865914
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any gender
  • People who have been clinically diagnosed with type 2 diabetes
  • People who have signs of kidney problems, such as protein in the urine (at low or higher levels) or reduced kidney function
  • People who have had a kidney biopsy with a complete kidney tissue diagnosis
  • People who have signed a consent form agreeing to take part in the trial

Who may not be able to join:

  • People whose medical history records are incomplete
  • People who have been diagnosed with a kidney disease caused by something other than diabetes
  • People who have an inherited (genetic) kidney disease
  • People who have an autoimmune disease (where the immune system attacks the body's own tissues)
  • People with cancer who are expected to survive less than 6 months
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xiangmei Chen, MD.&Ph.D, Chinese PLA General Hospital

Phone: +86 010 66935462

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Chinese PLA General Hospital
Registry
ClinicalTrials.gov
Start date
30 November 2017
Est. completion
30 November 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

change in eGFR and urine protein from baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov